Insmed's stock price surged 5.78% during intraday trading on Wednesday, marking a significant rebound for the biopharmaceutical company.

The sharp rise was driven by two key positive developments. First, RBC Capital Markets published a research note stating that the selloff following Insmed's Q1 earnings release was an overreaction, maintaining its Outperform rating on the stock. Second, Fidelity Investments (FMR LLC) filed a disclosure revealing a new significant position in Insmed, signaling strong institutional capital inflow and boosting market confidence.

These developments come after the stock had declined approximately 29% following its Q1 earnings release, with analysts suggesting the current price presents a recovery opportunity from oversold levels.